New Study: Stem Cell Field is Infected with Hype
By Michael Hiltzik,
Los Angeles Times
| 03. 31. 2015
Untitled Document
When billions of dollars are at stake in scientific research, researchers quickly learn that optimism sells.
A new study published in Science Translational Medicine offers a window into how hype arises in the interaction between the media and scientific researchers, and how resistant the hype machine is to hard, cold reality. The report's focus is on overly optimistic reporting on potential stem cell therapies. Its findings are discouraging.
The study by Timothy Caulfield and Kalina Kamenova of the University of Alberta law school (Caulfield is also on the faculty at the school of public health) found that stem cell researchers often ply journalists with "unrealistic timelines" for the development of stem cell therapies, and journalists often swallow these claims uncritically.
The authors mostly blame the scientists, who need to be more aware of "the importance of conveying realistic ... timelines to the popular press." We wouldn't give journalists this much of a pass; writers on scientific topics should understand that the development of drugs and therapies can take years and involve myriad dry holes and dead ends. They should be vigilant against gaudy promises.
That's especially true in stem...
Related Articles
By Ryan Cross, Endpoints News | 09.02.2026
The deaths of two children who received CRISPR therapies in China have rattled scientists who work on similar genetic medicines in the US, adding new fuel to a yearslong debate about the danger of the gene therapy field’s most-used delivery...
By Maia Hibbett, Wired | 09.09.2026
THE INSTAGRAM POST, precision-guided by sex and age, had zeroed in on its target. Yuchen Tu is a conservatory-trained viola player from Chongqing, China, a lover of science fiction, and an aspiring member of the US Army Reserve Officer Training...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Claire Robinson and Jonathan Matthews, Guest Contributors
| 08.25.2026
This is an excerpt of an article originally published on August 1, 2026 at GMWatch.
A six-year-old girl has died in a gene editing gene therapy trial in China that went wrong, the journal Science reports. Seven days after the girl's medical team infused trillions of viruses carrying the recipe for the gene editing tool – in this case a base editor – into her spinal fluid, she died of a severe immune reaction linked to the therapy.
Just...